Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1606-1611

  Marani, Carlo ^a   Clavio, Marino ^a   Grasso, Raffaella ^a   Colombo, Nicoletta ^a   Guolo, Fabio ^a   Kunkl, Annalisa ^a   Ballerini, Filippo ^a   Giannoni, Livia ^a   Ghiggi, Chiara ^a   Fugazza, Giuseppina ^a   Ravetti, Jean Louis ^a   Gobbi, Marco ^a   Miglino, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute myeloid leukemia; Early response assessment; Flow cytometry; Minimal residual disease; Prognosis; Wilms' tumor gene

Indexed keywords

CYTARABINE; FLUDARABINE; IDARUBICIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; WILMS TUMOR GENE 1;

EID: 84888135840     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.005     Document Type: Article

References (28)

1. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. Mrózek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109(January (2)):431-448.
3. Grimwade D., Vyas P., Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010, 22:656-663.
4. Cilloni D., Renneville A., Hermitte F., Hills R.K., Daly S., Jovanovic J.V., et al. Real-Time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet Study. J Clin Oncol 2009, 27:5195-5201.
5. Lapillonne H., Renneville A., Auvrignon A., Flamant C., Blaise A., Perot C., et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006, 24:1507-1515.
6. Buccisano F., Maurillo L., Spagnoli A., Del Principe M.I., Fraboni D., Panetta P., et al. Cytogenetic and molecular diagnostic characterization combined to post consolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010, 116:2295-2303.
7. San Miguel J.F., Vidriales M.B., López-Berges C., Díaz-Mediavilla J., Gutiérrez N., Cañizo C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98(September (6)):1746-1751.
8. Rubnitz J.E., Inaba H., Dahl G., Ribeiro R.C., Bowman W.P., Taub J., et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010, 11:543-552.
9. Yin J.A., O'Brien M.A., Hills R.K., Daly S.B., Wheatley K., Burnett A.K. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012, 120(October (14)):2826-2835.
10. Gallagher R.E., Yeap B.Y., Bi W., Livak K.J., Beaubier N., Rao S., et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003, 101(April (7)):2521-2528.
11. Miglino M., Colombo N., Grasso R., Marani C., Clavio M., Pica G.M., et al. Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. Leuk Lymphoma 2012, 53(November (11)):2214-2217.
12. Abdelhamid E., Preudhomme C., Helevaut N., Nibourel O., Gardin C., Rousselot P., et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res 2012, 36(March (3)):316-323.
13. Østergaard M., Olesen L.H., Hasle H., Kjeldsen E., Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004, 125(June (5)):590-600.
14. Ommen H.B., Nyvold C.G., Braendstrup K., Andersen B.L., Ommen I.B., Hasle H., et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008, 141(June (6)):782-791.
15. Garg M., Moore H., Tobal K., Liu Yin J.A. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003, 123(October (1)):49-59.
16. Trka J., Kalinová M., Hrusák O., Zuna J., Krejcí O., Madzo J., et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002, 16:1381-1389.
17. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998, 92(7):2322-2333.
18. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009, 38:5-395.
19. Clavio M., Vignolo L., Albarello A., Varaldo R., Pierri I., Catania G., et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007, 138(July (2)):186-195.
20. Macedo A., Orfao A., Ciudad J., Gonzalez M., Vidriales B., Lopez-Berges M.C., et al. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995, 9(November (11)):1896-1901.
21. Macedo A., Orfão A., Gonzalez M., Vidriales M.B., López-Berges M.C., Martínez A., et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995, 9(June (6)):993-998.
22. Al-Mawali A., Gillis D., Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009, January (131)(1):16-26.
23. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93(May (9)):3074-3080.
24. Miglino M., Colombo N., Pica G., Grasso R., Clavio M., Bergamaschi M., et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 2011, 52(October (10)):1961-1969.
25. Coustan-Smith E., Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia?. Curr Opin Hematol 2013, 20(March (2)):86-92.
26. Buccisano F., Maurillo L., Gattei V., Del Poeta G., Del Principe M.I., Cox M.C., et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006, 20(10):1783-1789.
27. Gianfaldoni G., Mannelli F., Ponziani V., Longo G., Bencini S., Bosi A., et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010, 95(May (5)):833-836.
28. Rossi G., Minervini M.M., Carella A.M., de Waure C., di Nardo F., Melillo L., et al. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res 2012, 36(April (4)):401-406.